Browsing Tag
avutometinib
1 post
Verastem Oncology’s avutometinib plus defactinib trial in LGSOC published in JCO with robust clinical responses
Verastem Oncology published pivotal Phase 2 RAMP 201 trial results in JCO, showing strong response rates for avutometinib plus defactinib in recurrent LGSOC.